Annals of Pharmacotherapy最新文献_第3页

Persistence Within 6P Medicine Model Has Value for Clinical Decision Only When Adherence Is Assessed. 在6P医学模型中，只有当依从性被评估时，才具有临床决策价值。

IF 2.3 4区医学

Annals of Pharmacotherapy Pub Date : 2025-08-17 DOI: 10.1177/10600280251363950

Joaquín Borrás-Blasco, Esther Ramírez-Herráiz, Andrés Navarro-Ruiz

引用次数: 0

Evaluation of Drug-Drug Interactions of Modafinil and Armodafinil with Concurrent Antiretroviral Therapies: A Case Series. 莫达非尼和阿莫达非尼并发抗逆转录病毒治疗的药物-药物相互作用评价：一个病例系列。

IF 2.3 4区医学

Annals of Pharmacotherapy Pub Date : 2025-08-09 DOI: 10.1177/10600280251361582

Addison B Taylor, Anne M Masich, Patricia Pecora Fulco

引用次数: 0

Cardiac Adverse Events Associated With Elotuzumab: A Disproportionality Analysis Using FDA Adverse Event Reporting System. 与Elotuzumab相关的心脏不良事件：使用FDA不良事件报告系统的歧化分析。

IF 2.3 4区医学

Annals of Pharmacotherapy Pub Date : 2025-08-04 DOI: 10.1177/10600280251359849

Muhammed Favas K T, Beema T Yoosuf, Dipika Bansal

引用次数: 0

Reversing Anticoagulants: Influence of Anticoagulation Stewardship and Key Considerations for Optimizing Outcomes. 逆转抗凝剂：抗凝管理的影响和优化结果的关键考虑因素。

IF 2.3 4区医学

Annals of Pharmacotherapy Pub Date : 2025-08-03 DOI: 10.1177/10600280251356019

William E Dager, Megan A Rech, Brian W Gilbert

引用次数: 0

Travoprost Intracameral Implant: A Review on the Novel Treatment Modality for Open-Angle Glaucoma and Ocular Hypertension. 曲伏前列素眼内植入治疗开角型青光眼和高眼压的新方法综述。

IF 2.3 4区医学

Annals of Pharmacotherapy Pub Date : 2025-08-01 Epub Date: 2024-12-10 DOI: 10.1177/10600280241291911

Jessica Huston, Mark Paauw, Dontia Orey, Aliya Centner, Azeem Hasan, Rajesh Shetty, Kathryn Freidl, Rebecca Goldfaden

{"title":"Travoprost Intracameral Implant: A Review on the Novel Treatment Modality for Open-Angle Glaucoma and Ocular Hypertension.","authors":"Jessica Huston, Mark Paauw, Dontia Orey, Aliya Centner, Azeem Hasan, Rajesh Shetty, Kathryn Freidl, Rebecca Goldfaden","doi":"10.1177/10600280241291911","DOIUrl":"10.1177/10600280241291911","url":null,"abstract":"Objective: This article reviews the published data encompassing the development, pharmacology, efficacy, and safety of travoprost, intracameral implant, a treatment for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension.Data sources: A literature search was conducted from drug discovery until September 2024 through PubMed, MEDLINE, and National Institutes of Health Clinical Trials Registry utilizing the following search terms: iDose, travoprost, intracameral implant, OTX-TIC, open-angle glaucoma, and ocular hypertension.Study selection and data extraction: All relevant English-language studies, or studies that could be appropriately translated into English, containing the pharmacology, pharmacokinetics, safety, and efficacy of travoprost intracameral implant were selected for review.Data synthesis: Travoprost implants showed significant reductions in IOP compared with other treatment options with fewer limitations often associated with topical medications resulting in travoprost implant patients favoring reduced concomitant use of topical IOP-lowering medications (with 81% of patients being medication free).Relevance to Patient Care and Clinical Practice in Comparison with Existing Drugs:Due to limited compliance with topical treatment modalities, the travoprost implant presents a promising alternative pathway for drug delivery. With a duration of 3 years and removal of the need for patient dexterity and application compliance, the travoprost implant serves an unmet need for patients and prescribers.Conclusion: Travoprost intracameral implant is a safe and effective delivery system for intracameral travoprost administration for patients with OAG or ocular hypertension.","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"767-772"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Use of Protamine for the Management of Postcardiac Surgery Coagulopathy. 鱼精蛋白在心脏手术后凝血功能障碍治疗中的应用。

IF 2.3 4区医学

Annals of Pharmacotherapy Pub Date : 2025-08-01 Epub Date: 2024-12-18 DOI: 10.1177/10600280241302324

Minlang Lin, Michael Militello, Benjamin Hohlfelder, Kevin Hodges, Jessica Ward

引用次数: 0

Doxycycline Versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus Aureus-Associated Acute Pulmonary Exacerbations in People With Cystic Fibrosis. 多西环素与万古霉素治疗囊性纤维化患者耐甲氧西林金黄色葡萄球菌相关急性肺恶化

IF 2.3 4区医学

Annals of Pharmacotherapy Pub Date : 2025-08-01 Epub Date: 2025-01-08 DOI: 10.1177/10600280241310595

Kendall H Brickel, Denise Kelley, Theresa Jaso, Hai Quyen Tran, Jason Fullmer, Danielle Beachler, Steven Wulfe

{"title":"Doxycycline Versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus Aureus-Associated Acute Pulmonary Exacerbations in People With Cystic Fibrosis.","authors":"Kendall H Brickel, Denise Kelley, Theresa Jaso, Hai Quyen Tran, Jason Fullmer, Danielle Beachler, Steven Wulfe","doi":"10.1177/10600280241310595","DOIUrl":"10.1177/10600280241310595","url":null,"abstract":"Background: Among people with cystic fibrosis (PwCF), methicillin-resistant Staphylococcus aureus (MRSA)-associated acute pulmonary exacerbations (APEs) have been increasing in prevalence and can cause rapid declines in lung function and increased mortality. Fortunately, since 2019, incidence has started to decline.Objective: The purpose of this study was to evaluate if doxycycline has comparable efficacy to vancomycin for the treatment of APEs in PwCF. Given the potential toxicities and intolerances associated with vancomycin, evaluating alternative therapies such as doxycycline is warranted.Methods: A multicenter retrospective cohort study was conducted in adult and pediatric PwCF who received greater than 48 hours of either vancomycin or doxycycline to treat MRSA-associated APEs between May 1, 2014, and August 31, 2021. The primary outcome was the number of PwCF with a return to ≥90% of baseline forced expiratory volume in the first second (FEV1).Results: There were 229 PwCF encounters screened, of which 89 met inclusion criteria (n = 26, vancomycin; n = 63, doxycycline). There were no differences between vancomycin and doxycycline for the primary outcome: 18/26 (69.2%) in the vancomycin group vs 51/63 (81.0%) in the doxycycline group (P = 0.23). Secondary outcomes were similar between groups, including no difference in incidence of acute kidney injury (AKI), although a significantly higher incidence of adverse events occurred in the vancomycin arm.Conclusion and relevance: The findings of this study suggest doxycycline may be a reasonable alternative to vancomycin for MRSA-associated APEs, particularly in PwCF who may not tolerate vancomycin or who require concomitant nephrotoxins such as intravenous (IV) aminoglycosides.","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"685-693"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142942880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pivmecillinam for Uncomplicated Acute Cystitis: A Contemporary Review. 匹美西林治疗无并发症急性膀胱炎：当代综述。

IF 2.3 4区医学

Annals of Pharmacotherapy Pub Date : 2025-08-01 Epub Date: 2024-12-07 DOI: 10.1177/10600280241288554

Jessica E Burchette, Kelly Covert, Patrick Tu, Bryan P White, Daniel B Chastain, David B Cluck

{"title":"Pivmecillinam for Uncomplicated Acute Cystitis: A Contemporary Review.","authors":"Jessica E Burchette, Kelly Covert, Patrick Tu, Bryan P White, Daniel B Chastain, David B Cluck","doi":"10.1177/10600280241288554","DOIUrl":"10.1177/10600280241288554","url":null,"abstract":"Objective: To review the evidence and discuss use of pivmecillinam in uncomplicated acute cystitis.Data sources: A literature search was conducted utilizing PubMed (from 2000 through August 2024) and ClinicalTrials.gov. Medical Subject Headings (MeSH) terms, such as mecillinam or pivmecillinam and urinary tract infections, were utilized. Additional references were identified by reviewing literature citations.Study selection and data extraction: Articles were limited to English language publications evaluating the efficacy or safety of pivmecillinam for urinary tract infections (UTIs) in adult populations.Data synthesis: Data from 6 randomized controlled trials support pivmecillinam for acute uncomplicated cystitis at doses of 200 to 400 mg 3 times daily for 3 to 7 days, with more consistent clinical and bacteriologic cure observed with 400 mg doses and longer therapy durations. Clinical evaluation of 400 mg 2 to 3 times daily is available with use more common in non-US Food and Drug Administration (FDA)-approved populations, such as men, pregnancy, and multidrug resistant infections. There are limited data supporting pivmecillinam for pyelonephritis; routine use is cautioned until further clinical data are available.Relevance to patient care and clinical practice in comparison with existing drugs:As resistance to first-line antimicrobials rises, the need for safe and effective treatment options remains high. Pivmecillinam represents a new therapeutic option available in the United States for outpatient management of uncomplicated acute cystitis.Conclusion: Pivmecillinam could be a key agent for uncomplicated acute cystitis. Utilization will likely be cost driven, but the promise of low resistance encourages the place in therapy when other agents are not susceptible to infecting uropathogens.","PeriodicalId":7933,"journal":{"name":"Annals of Pharmacotherapy","volume":" ","pages":"743-757"},"PeriodicalIF":2.3,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correspondence: Exogenous Thyroid Hormones and Dementia Symptoms. 对应：外源性甲状腺激素和痴呆症状。

IF 2.3 4区医学

Annals of Pharmacotherapy Pub Date : 2025-08-01 Epub Date: 2025-01-06 DOI: 10.1177/10600280241310434

Minh-Hoang Tran, Kim-Huong Truong-Nguyen

引用次数: 0

Weighing in on the Recent Approval of Tenecteplase for Acute Ischemic Stroke: Significance of Body Weight and the New Dosing Schedule. 权衡最近批准的替奈普用于急性缺血性卒中：体重的意义和新的给药方案。

IF 2.3 4区医学

Annals of Pharmacotherapy Pub Date : 2025-07-29 DOI: 10.1177/10600280251361357

Harn J Shiue, Oana M Dumitrascu, Kara A Sands

引用次数: 0